Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VERT is on the bid. That's a good sign.
Looks like 7s will be gone before the day ends.
Congrats on your 10M position. I added 2M at .0006 today and I also have a bunch more bidding at .0005. I'll continue to provide support at .0005 and smack the asks at .0006 until the news comes.
Different people have different trading strategies. Some are happy with a profit of a few ticks. They roam the around different boards everyday to find that few ticks. They have no regard for the fundamentals of the companies that they invest in. On the other hand, there are some people who once they find a great company, they invest in the long term. I'm the type of people that belong to the latter.
At the end of the day, it is up to each individual person to be responsible for his/her own decision. Therefore, you can't blame other people for what they do.
Once the news starts flowing, all kind of investors will show up. NNRX is now a new company with the new CEO at the helm. Give it some time. I'm holding a big position and not even worry about the day to day price movement.
The new CEO just took over for 3 weeks. Give him some time to get settled down and get the ball rolling.
VNDM moved with 10K share smack...lol.
NNRX's Products Can Be Bought Here:
http://www.amazon.com/s/ref=sr_so_2?rh=n%3A3760901%2Ck%3ANutranomics%2Cp_89%3ANutranomics&keywords=Nutranomics&ie=UTF8&qid=1445441303
http://bodyzenbalance.com/harmony-health-services-nutranomics-products/
http://www.luckyvitamin.com/p-644852-nutranomics-viraguard-dietary-supplement-60-capsules?redirect=1
https://www.pureformulas.com/search?Ntt=Nutranomics
http://www.lazada.com.ph/nutranomics/
http://iprice.ph/nutranomics/
GenEpic PBS Special & Other Links
1) GenEpic PBS Special
I speculate news to come out later this week or early next week about the CEO buying up all the debt.
At the moment, NNRX has only one stock class which is common. But if they want to create another class for preferred, then I might join you. Let me know if they get back to you.
We'll join the millionaire club at silver.
Breynolds,
Congrats on your holdings. Between you, iancnyc, and myself, we are accounted for 10% of the OS.
That water thing stayed stagnate months. The revenues are the same when compared to that water, but NNRX has much higher profit margin at 65%. In addition, the Share Structure is awesome here and we have a new CEO here who has money and business savvy to turn this company around. I think NNRX's dark days are history and it's a new dawn and new day for NNRX.
Hi Iancnyc,
Glad to see you here. I think we have found a great one here.
Looks like someone lost patience and sold out.
NNRX can run multiple hundred percents in one day especially with this tiny Share Structure:
O/S = 480M
A/S = 750M
With a CEO who has the money and business know-hows at the helm, anything is possible.
I'm sure it will happen within the next week or two. Once it does, NNRX will be the talk of the investment community and remain there for a long time.
Looks like you read a different letter than the rest of us. But if you keep posting the same old thing everyday then I'll be humble and dumb it down for you. I usually don't do this but, it's an exception for you today.
Since we have received a number of comments and questions from shareholders on the potential action to reverse split our shares, let me provide you our insights. Our consideration of such was not a shareholder request recover additional, dilutive share issuances only to issue more shares. Rather, this consideration was an effort to position our stock to meet listing requirement on OTC Markets' QB and other National Exchanges like Nasdaq and NYSE. We believe we will obtain greater access to investors and potentially institutional investors with a cap structure and share price greater than current pricing.
This, however is down the road at best. For now, the below is our basic plan;
1. Rebuild Nutranomics' sales and communicate our efforts
2. Diminish or eliminate dilutive financing structures currently in place
3. Finance our business with new capital
4. Report our successes each step of the way
Salaries & wages = $931,499
Interest expense = $350,197
----------------------------
Total = $1,281,696
These 2 expense items alone accounted for almost $1.3M. That's outrages. No wonder why the share price plummeted from pennies to trip. I didn't invest a penny while NNRX was still under the old CEO.
I only invested recently when Dr. Eyring replaced the old CEO. Dr. Eyring is a business savvy and he has already taken steps to reduce these expenses:
"The day I assumed office, I dismissed underperforming staff, began scripting an employee handbook, defined job requirements and reviewed the balance of W-2 versus 1099 staff. In the weeks after, we audited our supply chain, manufacturing, inventory, pricing and reviewed credit lines for customers and our own with our creditors and banks. We cut, trimmed, streamlined and found savings never before realized. Our work resulted in significant reductions of operating costs, and in one such case, we found an available cost reduction of 30% on our leading products. We expect to realize these financial benefits and others in the coming quarters.
This was good news, but as mentioned above, if we could not leverage sales growth in this new paradigm, all the process efficiencies and cost saving measures would not benefit our shareholders. We then looked at every aspect of our product lines and their sales. We endeavored to complete a new order processing and CRM system to market, sell, deliver and service our customers. We studied customer purchasing patterns and trends in the market and engaged the Hamacher Group to update our brand and positioning for our current and future products we will launch. We negotiated an exclusive worldwide license for GenEpic® and refocused Dr. Gibbs onto OEM and formulation sales. At this moment, Dr. Gibbs is in Asia actively securing orders for our OEM and Formulation Division.
Our last 10-Q showed the decline in year-over-year sales we must reverse first and before we enter our next growth stage. This need is critical for our staff, our shareholders and our customers. For those of you who reviewed the terms of my employment contract disclosed in our recent Current Report on Form 8-K filed with the SEC, I am also staking my compensation directly on measured increases in sales. I believe the plans above will help us meet them.
Our stock has suffered over the last year. News and updates were scattered due to ongoing declines in sales to new customers and our lack of new products developed for the billion-dollar nutraceutical market in which we compete. Our stock price continually retreated due to the financing structures once available to us to pay for mandatory public market costs and listing requirements. Maintaining our listing, reporting and compliance remained important to us and critical to our shareholders. It is for this reason, I am addressing you today. We qualified and quantified each of the financings which may have dilutive effects in the future. I say "may" because it is our intent to pay them off if possible, all of them, with capital I plan to personally inject into NNRX in the coming weeks. I cannot disclose more of these details but certainly will in an 8-K and press release as appropriate."
NNRX is reborn with Dr. Eyring at the helm and future of NNRX looks brighter and brighter day after day. That's why I'm here.
That's was old and things are starting to change with the new CEO (Dr. Eyring) at the helm. I'm here for the future of NNRX.
Unlike most of the companies in the OTC where managements sell people the dreams while dumping their shares in the billions, NNRX is a well established company with real products and revenues. The previous CEO under performed for the company.
Then came Dr. Joe Eyring, the new CEO, who is a go-getter type of person (if you read his Shareholder Letter released yesterday). It feels like NNRX is reborn with Dr. Eyring at the helm. He puts his money where is mouth is.
Therefore, if you buy and hold long, anything can happen.
NNRX has had Revenues of $1,345,110 in the last 9 months ending in April 30th. The profit margin is 65%. That's huge.
The CEO's goal is to generate $1.3M in revenues from October 1 - December 31 alone.
O/S = 480M
A/S = 750M
Amazing Shareholder Letter:
Nutranomics, Inc. Issues Shareholder Letter
Newly-Appointed, CEO and President, Dr. Edward "Joe" Eyring Details Immediate Actions and Improvements to Operations
DRAPER, UT -- (Marketwired) -- 10/14/15 -- Nutranomics, Inc. (OTC PINK: NNRX) ("Nutranomics" or "The Company"), a diversified nutraceutical formulator, supplement manufacturer and marketer of Nutranomics® health supplements, today issued a Shareholder Letter (the "Letter"). The Letter details challenges the Company endured during the last year, reports operational improvements to date, establishes strategies to regain sales momentum and provides options to finance the Company's growth.
Re: NNRX Shareholder Letter
Date: October 14, 2015
From: Dr. Edward "Joe" Eyring
Valued Shareholders,
I would like to acknowledge and thank those who wrote or spoke the words of support received after my appointment to CEO and President of Nutranomics, Inc. My intent is to continue to gain your trust over successive quarters as we rebuild our core business segments and reinvigorate others. I believe the plans and goals we have established as a team will result in revenue and earnings growth, an increase in the value of our stock and the ability to regain shareholders' and the market's confidence. All of these are typical CEO goals, but the skill for us to accomplish them is ultimately found in our operations as a company. For this reason, this letter focuses on this first and foremost.
As stated in the announcement last week, my work with Nutranomics included a three-month process during which time the Company provided me access to management, staff, customers, financials and suppliers. Dr. Tracy Gibbs and then Michael Doron each had solid business plans for the Company during their tenures, but I believe both gentlemen would agree that the Company's inability to achieve them detracted attention from that which Nutranomics should always do best. This is the researching, formulation, manufacturing, and marketing of Nutranomics®and GenEpic®-branded products plus securing NNRX formulation and OEM contracts. The forces that were preventing us from this core objective were many, but can be categorized by; ineffective sales and marketing plans, misaligned staffing, lack of manufacturing cost controls, pricing models which prevented us from being competitive and finally, poor cash flows as a direct result of the conditions above. After a decade of fast-growth, NNRX plateaued and was in decline. However, at its core was a committed team of employees devoted to the Company, its brand, and its mission to provide one of the best nutraceutical product lines to a growing list of customers worldwide. With this belief, I assumed an active management role in the Company.
The day I assumed office, I dismissed underperforming staff, began scripting an employee handbook, defined job requirements and reviewed the balance of W-2 versus 1099 staff. In the weeks after, we audited our supply chain, manufacturing, inventory, pricing and reviewed credit lines for customers and our own with our creditors and banks. We cut, trimmed, streamlined and found savings never before realized. Our work resulted in significant reductions of operating costs, and in one such case, we found an available cost reduction of 30% on our leading products. We expect to realize these financial benefits and others in the coming quarters.
This was good news, but as mentioned above, if we could not leverage sales growth in this new paradigm, all the process efficiencies and cost saving measures would not benefit our shareholders. We then looked at every aspect of our product lines and their sales. We endeavored to complete a new order processing and CRM system to market, sell, deliver and service our customers. We studied customer purchasing patterns and trends in the market and engaged the Hamacher Group to update our brand and positioning for our current and future products we will launch. We negotiated an exclusive worldwide license for GenEpic® and refocused Dr. Gibbs onto OEM and formulation sales. At this moment, Dr. Gibbs is in Asia actively securing orders for our OEM and Formulation Division.
Our last 10-Q showed the decline in year-over-year sales we must reverse first and before we enter our next growth stage. This need is critical for our staff, our shareholders and our customers. For those of you who reviewed the terms of my employment contract disclosed in our recent Current Report on Form 8-K filed with the SEC, I am also staking my compensation directly on measured increases in sales. I believe the plans above will help us meet them.
Our stock has suffered over the last year. News and updates were scattered due to ongoing declines in sales to new customers and our lack of new products developed for the billion-dollar nutraceutical market in which we compete. Our stock price continually retreated due to the financing structures once available to us to pay for mandatory public market costs and listing requirements. Maintaining our listing, reporting and compliance remained important to us and critical to our shareholders. It is for this reason, I am addressing you today. We qualified and quantified each of the financings which may have dilutive effects in the future. I say "may" because it is our intent to pay them off if possible, all of them, with capital I plan to personally inject into NNRX in the coming weeks. I cannot disclose more of these details but certainly will in an 8-K and press release as appropriate.
Since we have received a number of comments and questions from shareholders on the potential action to reverse split our shares, let me provide you our insights. Our consideration of such was not a shareholder request recover additional, dilutive share issuances only to issue more shares. Rather, this consideration was an effort to position our stock to meet listing requirement on OTC Markets' QB and other National Exchanges like Nasdaq and NYSE. We believe we will obtain greater access to investors and potentially institutional investors with a cap structure and share price greater than current pricing.
This, however is down the road at best. For now, the below is our basic plan;
1. Rebuild Nutranomics' sales and communicate our efforts
2. Diminish or eliminate dilutive financing structures currently in place
3. Finance our business with new capital
4. Report our successes each step of the way
I hope this initial communication has answered many of the questions asked of us over the last two weeks. While I always want to be shareholder-responsive, I have also enlisted the help of other seasoned professionals to do the same. I will speak to all of our shareholders in consistent intervals on conference calls, press and at investor events. When not doing so, I will be out getting orders and building our business with our new sales team. For this reason, please engage with our shareholder communications contacts and others below also charged to service your questions and requests.
We value your ownership of NNRX shares and appreciate your support of the actions and plans detailed in this letter to you. We will be back in touch, and more frequently, from this point onward.
Sincerely,
Dr. Edward "Joe" Eyring, M.D.
About Nutranomics Inc.
Nutranomics, Inc. (OTC PINK: NNRX) has been at the forefront of research and development of nutritional food products since its inception in 1995. In the first years of its operations, Nutranomics provided research and development of supplement formulations and nutraceuticals for domestic and international brands. After developing 100's of successful formulations and patents, Nutranomics developed its own brand of nutraceuticals in 1997, Nutranomics®, and began to market and sell its products directly to consumers and into retail outlets. Nutranomics maintains customers in the US, Canada, Taiwan, Japan, Singapore, Malaysia, Korea and Poland.
More than just a health supplement manufacturer, Nutranomics supports the worldwide community of people aiming for a healthy lifestyle by making education a core business philosophy.
Forward-Looking Statements:
Safe Harbor: This press release contains forward-looking information within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Nutranomics Inc., to be materially different from the statements made herein.
For the Company:
Matt Crowley Controller NURTANOMICS, INC. (OTC PINK : NNRX)
11487 S. 700 E
Draper, UT 84020
e: matt@nutranomics.com
p: (801) 576-8350
f: (801) 619-9060
w: www.nutranomics.com
Investor relations contact: John Mattio
Lamnia International for:
Nutranomics, Inc.
e: jmattio@lamniaintl.com
p: (203) 885-1058
w: www.lamniaintl.com
Source: Nutranomics Inc.
Well said Doc. People come and go for a few ticks, but I'll be here to reap the pennies reward.
From today's news.
"We negotiated an exclusive worldwide license for GenEpic® and refocused Dr. Gibbs onto OEM and formulation sales. At this moment, Dr. Gibbs is in Asia actively securing orders for our OEM and Formulation Division."
Looks like foreign investors are ready to buy in.
Agreed. The CEO wouldn't inject his own money into this company if he thinks it's a bad investment. Ignore the daily noise and keep your eyes on the prize. NNRX will trade in pennies shortly.
Lone Wolf,
After reading the news today. I wonder who that someone was that bought those 20M blocks without affecting the retail trades.
Our stock has suffered over the last year. News and updates were scattered due to ongoing declines in sales to new customers and our lack of new products developed for the billion-dollar nutraceutical market in which we compete. Our stock price continually retreated due to the financing structures once available to us to pay for mandatory public market costs and listing requirements. Maintaining our listing, reporting and compliance remained important to us and critical to our shareholders. It is for this reason, I am addressing you today. We qualified and quantified each of the financings which may have dilutive effects in the future. I say "may" because it is our intent to pay them off if possible, all of them, with capital I plan to personally inject into NNRX in the coming weeks. I cannot disclose more of these details but certainly will in an 8-K and press release as appropriate.
With today's news. All of the uncertainties have been removed. Only good news from here on out.
Costs already reduced by 30% (Profit margin is 65%, with this costs reduction, the profit margin is going to be over 80%). That's huge.
Increase sales
CEO will inject his own money to pay off debt
No R/S
That's huge. No CEO is going to invest his own money into the company unless he sees it as a great investment.
Nutranomics, Inc. Issues Shareholder Letter
Newly-Appointed, CEO and President, Dr. Edward "Joe" Eyring Details Immediate Actions and Improvements to Operations
DRAPER, UT -- (Marketwired) -- 10/14/15 -- Nutranomics, Inc. (OTC PINK: NNRX) ("Nutranomics" or "The Company"), a diversified nutraceutical formulator, supplement manufacturer and marketer of Nutranomics® health supplements, today issued a Shareholder Letter (the "Letter"). The Letter details challenges the Company endured during the last year, reports operational improvements to date, establishes strategies to regain sales momentum and provides options to finance the Company's growth.
Re: NNRX Shareholder Letter
Date: October 14, 2015
From: Dr. Edward "Joe" Eyring
Valued Shareholders,
I would like to acknowledge and thank those who wrote or spoke the words of support received after my appointment to CEO and President of Nutranomics, Inc. My intent is to continue to gain your trust over successive quarters as we rebuild our core business segments and reinvigorate others. I believe the plans and goals we have established as a team will result in revenue and earnings growth, an increase in the value of our stock and the ability to regain shareholders' and the market's confidence. All of these are typical CEO goals, but the skill for us to accomplish them is ultimately found in our operations as a company. For this reason, this letter focuses on this first and foremost.
As stated in the announcement last week, my work with Nutranomics included a three-month process during which time the Company provided me access to management, staff, customers, financials and suppliers. Dr. Tracy Gibbs and then Michael Doron each had solid business plans for the Company during their tenures, but I believe both gentlemen would agree that the Company's inability to achieve them detracted attention from that which Nutranomics should always do best. This is the researching, formulation, manufacturing, and marketing of Nutranomics®and GenEpic®-branded products plus securing NNRX formulation and OEM contracts. The forces that were preventing us from this core objective were many, but can be categorized by; ineffective sales and marketing plans, misaligned staffing, lack of manufacturing cost controls, pricing models which prevented us from being competitive and finally, poor cash flows as a direct result of the conditions above. After a decade of fast-growth, NNRX plateaued and was in decline. However, at its core was a committed team of employees devoted to the Company, its brand, and its mission to provide one of the best nutraceutical product lines to a growing list of customers worldwide. With this belief, I assumed an active management role in the Company.
The day I assumed office, I dismissed underperforming staff, began scripting an employee handbook, defined job requirements and reviewed the balance of W-2 versus 1099 staff. In the weeks after, we audited our supply chain, manufacturing, inventory, pricing and reviewed credit lines for customers and our own with our creditors and banks. We cut, trimmed, streamlined and found savings never before realized. Our work resulted in significant reductions of operating costs, and in one such case, we found an available cost reduction of 30% on our leading products. We expect to realize these financial benefits and others in the coming quarters.
This was good news, but as mentioned above, if we could not leverage sales growth in this new paradigm, all the process efficiencies and cost saving measures would not benefit our shareholders. We then looked at every aspect of our product lines and their sales. We endeavored to complete a new order processing and CRM system to market, sell, deliver and service our customers. We studied customer purchasing patterns and trends in the market and engaged the Hamacher Group to update our brand and positioning for our current and future products we will launch. We negotiated an exclusive worldwide license for GenEpic® and refocused Dr. Gibbs onto OEM and formulation sales. At this moment, Dr. Gibbs is in Asia actively securing orders for our OEM and Formulation Division.
Our last 10-Q showed the decline in year-over-year sales we must reverse first and before we enter our next growth stage. This need is critical for our staff, our shareholders and our customers. For those of you who reviewed the terms of my employment contract disclosed in our recent Current Report on Form 8-K filed with the SEC, I am also staking my compensation directly on measured increases in sales. I believe the plans above will help us meet them.
Our stock has suffered over the last year. News and updates were scattered due to ongoing declines in sales to new customers and our lack of new products developed for the billion-dollar nutraceutical market in which we compete. Our stock price continually retreated due to the financing structures once available to us to pay for mandatory public market costs and listing requirements. Maintaining our listing, reporting and compliance remained important to us and critical to our shareholders. It is for this reason, I am addressing you today. We qualified and quantified each of the financings which may have dilutive effects in the future. I say "may" because it is our intent to pay them off if possible, all of them, with capital I plan to personally inject into NNRX in the coming weeks. I cannot disclose more of these details but certainly will in an 8-K and press release as appropriate.
Since we have received a number of comments and questions from shareholders on the potential action to reverse split our shares, let me provide you our insights. Our consideration of such was not a shareholder request recover additional, dilutive share issuances only to issue more shares. Rather, this consideration was an effort to position our stock to meet listing requirement on OTC Markets' QB and other National Exchanges like Nasdaq and NYSE. We believe we will obtain greater access to investors and potentially institutional investors with a cap structure and share price greater than current pricing.
This, however is down the road at best. For now, the below is our basic plan;
1. Rebuild Nutranomics' sales and communicate our efforts
2. Diminish or eliminate dilutive financing structures currently in place
3. Finance our business with new capital
4. Report our successes each step of the way
I hope this initial communication has answered many of the questions asked of us over the last two weeks. While I always want to be shareholder-responsive, I have also enlisted the help of other seasoned professionals to do the same. I will speak to all of our shareholders in consistent intervals on conference calls, press and at investor events. When not doing so, I will be out getting orders and building our business with our new sales team. For this reason, please engage with our shareholder communications contacts and others below also charged to service your questions and requests.
We value your ownership of NNRX shares and appreciate your support of the actions and plans detailed in this letter to you. We will be back in touch, and more frequently, from this point onward.
Sincerely,
Dr. Edward "Joe" Eyring, M.D.
About Nutranomics Inc.
Nutranomics, Inc. (OTC PINK: NNRX) has been at the forefront of research and development of nutritional food products since its inception in 1995. In the first years of its operations, Nutranomics provided research and development of supplement formulations and nutraceuticals for domestic and international brands. After developing 100's of successful formulations and patents, Nutranomics developed its own brand of nutraceuticals in 1997, Nutranomics®, and began to market and sell its products directly to consumers and into retail outlets. Nutranomics maintains customers in the US, Canada, Taiwan, Japan, Singapore, Malaysia, Korea and Poland.
More than just a health supplement manufacturer, Nutranomics supports the worldwide community of people aiming for a healthy lifestyle by making education a core business philosophy.
Forward-Looking Statements:
Safe Harbor: This press release contains forward-looking information within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Nutranomics Inc., to be materially different from the statements made herein.
For the Company:
Matt Crowley Controller NURTANOMICS, INC. (OTC PINK : NNRX)
11487 S. 700 E
Draper, UT 84020
e: matt@nutranomics.com
p: (801) 576-8350
f: (801) 619-9060
w: www.nutranomics.com
Investor relations contact: John Mattio
Lamnia International for:
Nutranomics, Inc.
e: jmattio@lamniaintl.com
p: (203) 885-1058
w: www.lamniaintl.com
Source: Nutranomics Inc.
Updated OS & Thoughts:
10/13/2015:Nutranomics O/S 481,780,758 A/S = 750,000,000
10/9/2015: Nutranomics O/S 462,314,091 A/S = 750,000,000
If you look at all of the transaction dates in today's 8-K, you can see that all of the shares HAD already been issued and accounted for in the latest OS update from the TA today.
If you look at the volume history, you can see that the run up started on 10/2/2015. Prior to 10/2, there were under 60 followers. As of today 10/13, there are 157 followers.
If you look further into today's 8-K, you can see that the holders converted shares 4 out of 5 days last week between 10/5 thru 10/8.
The questions I have are why did the holders stop converting on 10/9 and 10/12 and what is the need for the new CEO to issue an 8-K today to report all of the transactions in the past?
I think the new CEO has an alternative method to stop holders from converting and cleans up old stuff by releasing the 8-K today before releasing his shareholders update this week.
That's what I'm thinking too.
These were old but not filed. Just lumped all in one 8-K today paving the way for the new beginning with the new CEO.
Looks like the new CEO is doing clean house items before releasing the NEWS.
News could come out at any moment now.
"The Company and Dr. Eyring have committed to issuing a Shareholder Letter in the next 10 business day to update shareholders on and before October 17, 2015. The Shareholder Letter and update will provide more detail on Company strategies, plans for the immediate and near terms, future growth opportunities and also address shareholder questions recently received by the Company. The letter will be provided in press on financial wires and sent to shareholders who have provided electronic mail addresses to the Company."
We need bid support here.